Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2011

01-12-2011 | Original Paper

Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis

Authors: Yan-Jie Xu, Yong-Feng Shao, Xia Zhao, Yi-Ting Geng, Kai Wang, Yong-Mei Yin

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2011

Login to get access

Abstract

Background

The human epidermal growth factor receptor 2 (HER-2) and leptin/OB-R system have been reported to be intertwined in several cancer types. However, limited research has been conducted with regard to this interaction in lung cancers. In this study, we investigated the relationship between the expression levels of these proteins and the development, progression and prognosis of non-small-cell lung cancer (NSCLC).

Methods

The expression of leptin, OB-Rb and HER-2 was evaluated in 100 NSCLC specimens by immunohistochemistry, with normal lung tissue as controls. The relationships between their expression levels and clinicopathological factors were evaluated by correlation analysis. Univariate and multivariate analyses were used to determine the associations between the expression levels of these proteins and the survival of NSCLC patients.

Results

Leptin was expressed in 71 and 25% (P < 0.05) of NSCLC and normal lung tissues, respectively, while OB-Rb was expressed in 62 and 31% (P < 0.05), respectively. Overexpression of HER-2 was detected in 53% of NSCLC tissues versus 0% of normal lung tissues (P < 0.05). A significant association was found between the expression levels of leptin and OB-Rb (P = 0.024), and between tumor-node-metastasis (TNM) stage and HER-2 expression (P = 0.003). Univariate survival analysis showed that TNM stage (P < 0.001) and leptin expression (P = 0.009) influenced survival time. Multivariate analysis suggested that TNM stage [hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.30–2.04, P < 0.001] and leptin expression (HR 1.69, 95% CI 1.01–2.80, P = 0.044) were independent prognostic factors for NSCLC.

Conclusions

The expression of leptin, OB-Rb and HER-2 was significantly higher in NSCLC tissues than in normal lung tissues. The expression of leptin is an independent prognostic factor for NSCLC.
Literature
go back to reference Bouloumié A, Drexlerh C, Lafontan M, Busse R (1998) Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83:1059–1066PubMed Bouloumié A, Drexlerh C, Lafontan M, Busse R (1998) Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83:1059–1066PubMed
go back to reference Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278:28668–28676PubMedCrossRef Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278:28668–28676PubMedCrossRef
go back to reference Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N (2008) Leptin signaling in breast cancer: an overview. J Cell Biochem 105:956–964PubMedCrossRef Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N (2008) Leptin signaling in breast cancer: an overview. J Cell Biochem 105:956–964PubMedCrossRef
go back to reference Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman B, Gertler A (2004) Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 565:139–142PubMedCrossRef Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman B, Gertler A (2004) Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 565:139–142PubMedCrossRef
go back to reference Fijolek J, Wiatr E, Rowinska-Zakrewska E, Giedronowicz D, Langfort R, Chabowski M, Orłowski T, Roszkowski K (2006) P53 and Her2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 21:81–87PubMed Fijolek J, Wiatr E, Rowinska-Zakrewska E, Giedronowicz D, Langfort R, Chabowski M, Orłowski T, Roszkowski K (2006) P53 and Her2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 21:81–87PubMed
go back to reference Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto GL, Surmacz E (2008) Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 8:305PubMedCrossRef Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto GL, Surmacz E (2008) Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 8:305PubMedCrossRef
go back to reference Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23:143–152PubMedCrossRef Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23:143–152PubMedCrossRef
go back to reference Giatromanolaki A, Koukourakis MI, O’Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC (1996) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 16:3819–3825PubMed Giatromanolaki A, Koukourakis MI, O’Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC (1996) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 16:3819–3825PubMed
go back to reference Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF (2002) Prognostic value of immunohistochemical expression of P53, HER2/neu and bcl-2 in stage 1 non-small cell lung cancer. Hum Pathol 33:105–110PubMedCrossRef Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF (2002) Prognostic value of immunohistochemical expression of P53, HER2/neu and bcl-2 in stage 1 non-small cell lung cancer. Hum Pathol 33:105–110PubMedCrossRef
go back to reference Hayes DF, Thor AD (2002) C-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29:231–245PubMedCrossRef Hayes DF, Thor AD (2002) C-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29:231–245PubMedCrossRef
go back to reference Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002) Her2/neu expression in malignant lung tumors. Semin Oncol 29:51–58PubMedCrossRef Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002) Her2/neu expression in malignant lung tumors. Semin Oncol 29:51–58PubMedCrossRef
go back to reference Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS (2006) Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 33:66–71PubMedCrossRef Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS (2006) Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 33:66–71PubMedCrossRef
go back to reference Ishikawa M, Kitayama J, Nagawa H (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10:4325–4331PubMedCrossRef Ishikawa M, Kitayama J, Nagawa H (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10:4325–4331PubMedCrossRef
go back to reference Janeckova R (2001) The role of leptin in human physiology and pathophysiology. Physiol Res 50:443–459PubMed Janeckova R (2001) The role of leptin in human physiology and pathophysiology. Physiol Res 50:443–459PubMed
go back to reference Kern J, Slebos R, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516–520PubMedCrossRef Kern J, Slebos R, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516–520PubMedCrossRef
go back to reference Kristiansen G, Yu Y, Petersen S, Kaufmann O, Schlüns K, Dietel M, Petersen I (2001) Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer 37:1089–1095PubMedCrossRef Kristiansen G, Yu Y, Petersen S, Kaufmann O, Schlüns K, Dietel M, Petersen I (2001) Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer 37:1089–1095PubMedCrossRef
go back to reference Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y (2010) The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 5:1922–1932PubMedCrossRef Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y (2010) The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 5:1922–1932PubMedCrossRef
go back to reference Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 83:584–594PubMedCrossRef Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 83:584–594PubMedCrossRef
go back to reference Nakamura H, Kawahara N, Taguchi M, Kabasawa K, Association of HER-2 Overexpression with Prognosis in Nonsmall Cell Lung Carcinoma (2005) A metaanalysis. Cancer 103:1865–1873PubMedCrossRef Nakamura H, Kawahara N, Taguchi M, Kabasawa K, Association of HER-2 Overexpression with Prognosis in Nonsmall Cell Lung Carcinoma (2005) A metaanalysis. Cancer 103:1865–1873PubMedCrossRef
go back to reference Ogunwobi O, Mutungi G, Beales IL (2006) Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2 mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147:4505–4516PubMedCrossRef Ogunwobi O, Mutungi G, Beales IL (2006) Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2 mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147:4505–4516PubMedCrossRef
go back to reference Pfeiffer P, Clausen PP, Andersen K, Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74:86–91PubMedCrossRef Pfeiffer P, Clausen PP, Andersen K, Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74:86–91PubMedCrossRef
go back to reference Saad RS, Liu Y, Han H, Landreneau RJ, Silverman JF (2004) Prognostic significance of HER2/neu, p53 and vascular endothelial growth factor expression in early stage conventional and bronchioalveolar carcinoma of the lung. Mod Pathol 17:1235–1242PubMedCrossRef Saad RS, Liu Y, Han H, Landreneau RJ, Silverman JF (2004) Prognostic significance of HER2/neu, p53 and vascular endothelial growth factor expression in early stage conventional and bronchioalveolar carcinoma of the lung. Mod Pathol 17:1235–1242PubMedCrossRef
go back to reference Scholl S, Beuzeboc P, Pouillart P (2001) Targeting HER-2 in other tumor types. Ann Oncol 12:S81–87PubMedCrossRef Scholl S, Beuzeboc P, Pouillart P (2001) Targeting HER-2 in other tumor types. Ann Oncol 12:S81–87PubMedCrossRef
go back to reference Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER-2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32:180–190PubMedCrossRef Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER-2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32:180–190PubMedCrossRef
go back to reference Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H (2007) Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 149:9–14PubMedCrossRef Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H (2007) Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 149:9–14PubMedCrossRef
go back to reference Surmacz E (2007) Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res 9:301PubMed Surmacz E (2007) Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res 9:301PubMed
go back to reference Terzidis A, Sergentanis TN, Antonopoulos G, Syrigos C, Efremidis A, Polyzos A, Dessypris N, Petridou ET (2009) Elevated serum leptin levels: a risk factor for non-small-cell lung cancer? Oncol 76:19–25CrossRef Terzidis A, Sergentanis TN, Antonopoulos G, Syrigos C, Efremidis A, Polyzos A, Dessypris N, Petridou ET (2009) Elevated serum leptin levels: a risk factor for non-small-cell lung cancer? Oncol 76:19–25CrossRef
go back to reference Zhao L, Shen ZX, Luo HS, Shen L (2005) Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma. World J Gastroenterol 11:7666–7670PubMed Zhao L, Shen ZX, Luo HS, Shen L (2005) Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma. World J Gastroenterol 11:7666–7670PubMed
Metadata
Title
Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis
Authors
Yan-Jie Xu
Yong-Feng Shao
Xia Zhao
Yi-Ting Geng
Kai Wang
Yong-Mei Yin
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1054-5

Other articles of this Issue 12/2011

Journal of Cancer Research and Clinical Oncology 12/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.